---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-077111"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:37:31.022552+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted

## Summary
- Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.
- Lead asset SPC-15 (intranasal PTSD treatment) pre-IND submitted for first-in-human trials.
- Pipeline also includes SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), SPU-16 (MS).
- Exclusive licenses from Columbia University (SPC-15, SPC-14) and University of Maryland (SPU-16).
- Company intends to use 505(b)(2) regulatory pathway for SPC-15 and SP-26 to shorten timelines.

## SEC filing metadata
- accession: 0001213900-24-077111
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/0001213900-24-077111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/ea0213917-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-077111
- JSON: https://secwatch.observer/filing/0001213900-24-077111.json
- Plain text: https://secwatch.observer/filing/0001213900-24-077111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.